Revagenix Doses First Patient in Phase 1 Rev-56 Trial
SAN FRANCISCO, Calif., July 27, 2026 Revagenix, Inc. announced that the first participant has been dosed in the Phase...
NIH
Advertisement
Merakris Therapeutics Wins NIH Funding for MTX-001
RESEARCH TRIANGLE PARK, N.C., July 21, 2026 Merakris Therapeutics announced that it has received a Direct-to-Phase II Small Business...
Primrose Bio Earns $2M NIH Award for RNA Therapeutics
SAN DIEGO, Calif., July 15, 2026 Primrose Bio, Inc. has secured a $2 million Direct-to-Phase II Small Business Innovation...
NIH Develops Blood Test to Predict Alzheimer’s Disease Progression
BETHESDA, Md., July 1, 2026 A National Institutes of Health (NIH)-funded study has identified a promising blood-based biomarker that...
CraniUS Secures NIH Grant for Glioblastoma Therapy
BALTIMORE, June 29, 2026 CraniUS Therapeutics has received an initial $1.1 million award through the National Institutes of Health...
Advertisements
NIH Study Reveals Brain Cells Driving Human Speech Activity
BETHESDA, Md., June 20, 2026 Researchers supported by the National Institutes of Health (NIH) have achieved a groundbreaking milestone...
Clear Scientific Gains FDA Fast Track for CS-1103
CAMBRIDGE, Mass., May 6, 2026 Clear Scientific Inc., a clinical-stage biopharmaceutical company developing innovative therapies for acute drug intoxication,...
MemorialCare Joins FASTEST Trial for Stroke Therapy
LONG BEACH, Calif., April 2026 MemorialCare Long Beach Medical Center has joined a nationwide Phase 3 clinical research effort...
NIH Launches East Palestine Health Research Program
EAST PALESTINE, Ohio, Feb. 3, 2026 — The National Institutes of Health (NIH), part of the U.S. Department of...
FDA Clears HDT Bio’s First-in-Class Tick-Borne Disease Vaccine
SEATTLE, Sept. 19, 2025 – HDT Bio Corporation has announced that the U.S. Food and Drug Administration (FDA) has...
Advertisement
